Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape-Reference-Cited by-同舟云学术

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

Published:2020-03-25 Issue:536 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Martin Constance J.¹^ORCID,Datta Abhishek¹,Littlefield Christopher¹,Kalra Ashish¹,Chapron Christopher¹,Wawersik Stefan¹,Dagbay Kevin B.¹^ORCID,Brueckner Christopher T.¹^ORCID,Nikiforov Anastasia¹^ORCID,Danehy Francis T.¹,Streich Frederick C.¹^ORCID,Boston Christopher¹^ORCID,Simpson Allison¹^ORCID,Jackson Justin W.¹^ORCID,Lin Susan¹^ORCID,Danek Nicole¹^ORCID,Faucette Ryan R.¹,Raman Pichai²,Capili Allan D.¹^ORCID,Buckler Alan¹^ORCID,Carven Gregory J.¹^ORCID,Schürpf Thomas¹^ORCID

Affiliation:

1. Scholar Rock, Inc., Cambridge, MA 02139, USA.

2. Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

Abstract

Inhibiting a specific isoform of TGFβ augments the effectiveness of checkpoint blockade therapy in cancer treatment.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference70 articles.

1. Cancer immunotherapy using checkpoint blockade

2. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.